Pacira BioSciences (PCRX) Restructuring Costs (2023 - 2024)
Pacira BioSciences (PCRX) posted quarterly Restructuring Costs of $1.2 million for Q3 2024, up 589.6% year-over-year from $173000.0 in Q4 2023, and up 19.3% quarter-over-quarter from $1.0 million in Q2 2024.
Pacira BioSciences (PCRX) Restructuring Costs (2023 - 2024) Analysis & Trends
Pacira BioSciences' Restructuring Costs history runs 2 years deep, the most recent figure standing at $1.2 million for Q3 2024.
- In Q3 2024, Restructuring Costs rose 589.6% year-over-year to $1.2 million; the TTM figure through Sep 2024 stood at $2.4 million (changed N/A YoY), while the FY2017 annual figure was $51.5 million, changed N/A from the prior year.
- Restructuring Costs for Q3 2024 stood at $1.2 million, up from $1.0 million in the prior quarter.
- The five-year high for Restructuring Costs was $1.2 million in Q3 2024, with the low at $173000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Pacira BioSciences | 945.90 Mn | 694.87 Mn | 148.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.19 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Sep 30, 2023 | 173,000.00 |